Simple Pharma acquires Testavan® and Vitaros®, two established men’s health brands, from Ferring.

St-Prex/London — Tuesday 16th February 2021 — Ferring Pharmaceuticals divests its full rights for Testavan® and Vitaros® to Simple Pharma.

By divesting its rights to Simple Pharma on this transaction, Ferring is able to focus on areas of high unmet need to bring the most value to patients and healthcare professionals.

“This is a landmark acquisition for Simple Pharma and demonstrates the relevance of our positioning as a go-to divestment partner for large pharmaceutical companies. We are looking forward to growing Testavan® and Vitaros® into a thriving men’s health franchise, while continuing to help pharmaceutical companies simplify their portfolio. Our digital operations platform allows us to integrate, manage, market, and grow products of any size, maintaining and expanding patient access to medicines.”

Nicolas Vennin & Charlie Bryant, Co-founders of Simple Pharma

“In an effort to streamline its focus on the highest unmet needs to bring the most value to patients and healthcare professionals, Ferring has revisited its broader urology portfolio and decided that Simple Pharma is the right company to take Testavan® and Vitaros® forward as part of their commitment to establishing a differentiated men’s health franchise. We will be working closely with Simple Pharma during the transition period to ensure continuity of supply for patients, and to ensure a smooth handover of the final regulatory authorisations.

Jan Peutzfeldt, Senior Vice President, Global Marketing & Business Development

The terms of the transaction are not disclosed.

About Simple Pharma

Simple Pharma is a pharmaceutical company founded in 2019 that specialises in the acquisition, integration, and commercialisation of products being divested by other pharmaceutical companies. This landmark acquisition of two established men’s health brands, Testavan® and Vitaros®, expands Simple Pharma’s distribution footprint to more than 30 countries worldwide.

Simple Pharma’s mission is to improve patient access to medicines by focusing on pharma operations. The team will seek to build on Ferring’s success in existing countries and launch in new territories to reach a wider patient and prescriber audience.

Learn more at, or connect with us on LinkedIn.

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, speciality biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and women’s health, and in speciality areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.

Media enquiries

If you have any questions or would like further information, please contact:



Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store
Simple Pharma

The Pharma industry’s go-to operations and divestment partner.